Article

Top 5 Common Endocrinology Practice Denials and Remedies

Do any of these 5 most common unexpected insurance denials (for June 2014) look familiar to you? Any of the top 5 reason codes? If so, is it time to look into why?

[[{"type":"media","view_mode":"media_crop","fid":"27340","attributes":{"alt":"","class":"media-image","id":"media_crop_2945187398225","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"2641","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","title":" ","typeof":"foaf:Image"}}]]

Each month, RemitDATA provides Physicians Practice with the latest data on unexpected denials - and the key reasons why - at medical practices nationwide.

This month, RemitDATA's vice president of product management, Aaron Hood, provides commentary for the data, with a specific focus on endocrinology, including recommendations to help your practice avoid future denials.

 

 

Related Videos
Yehuda Handelsman, MD: Insulin Resistance in Cardiometabolic Disease and DCRM 2.0 | Image Credit: TMIOA
Laurence Sperling, MD: Expanding Cardiologists' Role in Obesity Management  | Image Credit: Emory University
Schafer Boeder, MD: Role of SGLT2 Inhibitors and GLP-1s in Type 1 Diabetes | Image Credit: UC San Diego
Matthew J. Budoff, MD: Examining the Interplay of Coronary Calcium and Osteoporosis | Image Credit: Lundquist Institute
Alice Cheng, MD: Exploring the Link Between Diabetes and Dementia | Image Credit: LinkedIn
Matthew J. Budoff, MD: Impact of Obesity on Cardiometabolic Health in T1D | Image Credit: The Lundquist Institute
Jennifer B. Green, MD: Implementation of Evidence-Based Therapies for T2D | Image Credit: Duke University
Ralph A. DeFronzo, MD: Noxious Nine and Mifepristone for Hypercortisolism in T2D | Image Credit: LinkedIn
Diabetes Dialogue: Tirzepatide’s Long-Term Obesity Data | Image Credit: HCPLive
© 2025 MJH Life Sciences

All rights reserved.